Huntington National Bank Acquires 15,900 Shares of Stryker Co. (NYSE:SYK)

Huntington National Bank grew its stake in Stryker Co. (NYSE:SYK) by 5.9% in the 4th quarter, Holdings Channel reports. The institutional investor owned 283,703 shares of the medical technology company’s stock after buying an additional 15,900 shares during the quarter. Huntington National Bank’s holdings in Stryker were worth $102,148,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Chicago Capital LLC boosted its stake in Stryker by 3.1% in the 4th quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company’s stock worth $70,228,000 after purchasing an additional 5,841 shares during the period. Zhang Financial LLC boosted its position in shares of Stryker by 55.0% during the fourth quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock worth $41,366,000 after buying an additional 40,784 shares during the period. Appleton Partners Inc. MA grew its holdings in shares of Stryker by 5.0% during the fourth quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company’s stock worth $10,521,000 after buying an additional 1,400 shares in the last quarter. Metis Global Partners LLC lifted its stake in Stryker by 10.2% in the 4th quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company’s stock valued at $6,064,000 after acquiring an additional 1,561 shares in the last quarter. Finally, US Bancorp DE boosted its position in Stryker by 0.5% during the 4th quarter. US Bancorp DE now owns 182,825 shares of the medical technology company’s stock worth $65,829,000 after acquiring an additional 976 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.50% of the company’s stock.

Stryker Trading Up 0.3 %

Shares of NYSE:SYK opened at $373.20 on Wednesday. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The business has a 50 day moving average of $383.41 and a 200-day moving average of $374.43. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The stock has a market cap of $142.45 billion, a PE ratio of 48.09, a P/E/G ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the firm posted $3.46 earnings per share. As a group, equities research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.90%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is 43.30%.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Wells Fargo & Company lifted their price objective on shares of Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Citigroup reissued a “buy” rating and set a $450.00 price target on shares of Stryker in a research report on Wednesday, February 26th. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research report on Tuesday, February 18th. Stifel Nicolaus increased their price target on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Finally, Argus set a $450.00 price target on Stryker in a research report on Monday, February 3rd. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $421.90.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.